The benefit of biosimilar monoclonal antibodies in the therapy of inflammatory bowel diseases

Abstract

Summary: Nineteen years ago, the biosimilars, “copies” of the original therapeutic monoclonal antibodies, have been introduced in the clinical practice. The beginnig was associated with some confusion from health care providers, but today it is indisputable that their implementation in practice was one of the most significant changes that led to an increase in the availability of biological treatment, cost reduction and significant impact on management of patients with inflammatory bowel diseases. Key words: inflammatory bowel disease – biological treatment – biosimilars